NEW YORK (GenomeWeb) – Biocept today announced a $15 million common stock purchase agreement with Chicago-based Aspire Capital Fund.

The company said it plans to use the money raised to fund its general corporate activities, including research, development, and commercialization of its liquid biopsy tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.